4.57

2.97% -0.14

After Hours: 4.75 0.18 +3.94%

Macrogenics Inc (MGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Macrogenics Inc stock is traded at $4.57, with a volume of 833.48K. It is down -2.97% in the last 24 hours and up +16.88% over the past month. Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Previous Close:

$4.71

Open:

$4.9

24h Volume:

833.48K

Relative Volume:

0.74

Market Cap:

$290.48M

Revenue:

$157.08M

Net Income/Loss:

$-70.36M

P/E Ratio:

-4.1112

EPS:

-1.1116

Net Cash Flow:

$-71.69M

1W Performance:

-5.97%

1M Performance:

+16.88%

6M Performance:

+168.82%

1Y Performance:

+213.01%

1-Day Range:

$4.565

$5.06

1-Week Range:

$4.495

$5.06

52-Week Range:

$1.29

$5.08

Macrogenics Inc Stock (MGNX) Company Profile

Name

Macrogenics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

301-251-5172

Address

9704 MEDICAL CENTER DRIVE, Rockville, MD

Employee

293

Twitter

@macrogenics

Next Earnings Date

2026-08-13

Latest SEC Filings

MGNX's Discussions on Twitter

Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MGNX Macrogenics Inc	4.57	293.66M	157.08M	-70.36M	-71.69M	-1.1116
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Upgrade	B. Riley Securities	Neutral → Buy
Sep-17-25	Resumed	Barclays	Overweight
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-10-24	Downgrade	Stifel	Buy → Hold
May-10-24	Downgrade	TD Cowen	Buy → Hold
Apr-26-24	Initiated	B. Riley Securities	Buy
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-20-23	Upgrade	Citigroup	Neutral → Buy
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy
Feb-11-22	Initiated	BMO Capital Markets	Outperform
Feb-04-22	Initiated	SMBC Nikko	Outperform
Nov-17-21	Resumed	Guggenheim	Buy
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Oct-15-21	Resumed	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-12-21	Upgrade	Barclays	Underweight → Overweight
Dec-22-20	Resumed	H.C. Wainwright	Buy
Aug-03-20	Downgrade	Citigroup	Buy → Neutral
Jun-01-20	Upgrade	Guggenheim	Neutral → Buy
May-26-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Underweight
Dec-19-19	Initiated	Cantor Fitzgerald	Overweight
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight
Nov-21-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-20-19	Resumed	Guggenheim	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Guggenheim	Neutral
Feb-07-19	Upgrade	Citigroup	Sell → Buy
Feb-07-19	Downgrade	Wedbush	Outperform → Neutral
Feb-06-19	Upgrade	Raymond James	Underperform → Mkt Perform
Feb-04-19	Downgrade	Citigroup	Neutral → Sell
Dec-10-18	Downgrade	Raymond James	Outperform → Underperform
Sep-10-18	Resumed	BTIG Research	Buy
May-31-18	Initiated	Evercore ISI	Outperform
Mar-05-18	Initiated	H.C. Wainwright	Buy
Mar-31-17	Initiated	Raymond James	Outperform

View All

Macrogenics Inc Stock (MGNX) Latest News

Jun 29, 2026

MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enterprise value to revenue forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView

Jun 28, 2026

MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Price to earnings forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView

Jun 28, 2026

Enterprise value to revenue forward of MacroGenics, Inc. – BOATS:MGNX - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of MacroGenics, Inc. – BOATS:MGNX - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBIT forward of MacroGenics, Inc. – BOATS:MGNX - TradingView

Jun 27, 2026